Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | MYC | P01106 | 1/20 | 0.64 |
| ▸ | MAX | P61244 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343714 | 0.80 | RAB9A (0.63) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7569031 | 0.80 | PTPN7 (0.54) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL18695140 | 0.79 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6816225 | 0.79 | KMT2A (0.52) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1419684 | 0.79 | AR (0.54) | MAPTMEN1KMT2APLA2G1BATG4B | |
| SCHEMBL22289498 | 0.78 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL3299625 | 0.78 | MYC (1.00) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8612547 | 0.78 | MAOB (0.92) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL18807464 | 0.77 | MAOB (0.88) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8613032 | 0.77 | MAOB (0.83) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | MYC, MYCBP, MAX | MAPT 297/4885MEN1 6/4885KMT2A 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.